HK1202419A1 - Combination therapy with an antitumor alkaloid - Google Patents

Combination therapy with an antitumor alkaloid

Info

Publication number
HK1202419A1
HK1202419A1 HK15102897.3A HK15102897A HK1202419A1 HK 1202419 A1 HK1202419 A1 HK 1202419A1 HK 15102897 A HK15102897 A HK 15102897A HK 1202419 A1 HK1202419 A1 HK 1202419A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
antitumor alkaloid
alkaloid
antitumor
therapy
Prior art date
Application number
HK15102897.3A
Other languages
English (en)
Chinese (zh)
Inventor
Ocaa Victoria Moneo
Fernndez Luis Francisco Garca
Carlos Mara Galmarini
Navarro Mara Jos Guilln
Marn Pablo Manuel Avils
Nez Gema Santamara
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HK1202419A1 publication Critical patent/HK1202419A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK15102897.3A 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid HK1202419A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12

Publications (1)

Publication Number Publication Date
HK1202419A1 true HK1202419A1 (en) 2015-10-02

Family

ID=44936282

Family Applications (5)

Application Number Title Priority Date Filing Date
HK14101722.7A HK1188572A1 (zh) 2010-11-12 2014-02-24 抗腫瘤生物鹼的聯合治療
HK15102911.5A HK1202422A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid
HK15102897.3A HK1202419A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid
HK15102913.3A HK1202423A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid
HK15102907.1A HK1202421A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK14101722.7A HK1188572A1 (zh) 2010-11-12 2014-02-24 抗腫瘤生物鹼的聯合治療
HK15102911.5A HK1202422A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15102913.3A HK1202423A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid
HK15102907.1A HK1202421A1 (en) 2010-11-12 2014-02-24 Combination therapy with an antitumor alkaloid

Country Status (24)

Country Link
US (5) US20130266666A1 (xx)
EP (6) EP2786755A3 (xx)
JP (4) JP6382516B2 (xx)
KR (9) KR102247982B1 (xx)
CN (3) CN103282037B (xx)
AU (4) AU2011328004C1 (xx)
BR (4) BR122017028570B1 (xx)
CA (4) CA2995033C (xx)
CY (4) CY1117466T1 (xx)
DK (4) DK2786754T3 (xx)
ES (4) ES2790414T3 (xx)
HK (5) HK1188572A1 (xx)
HR (4) HRP20160361T1 (xx)
HU (4) HUE049389T2 (xx)
LT (3) LT2786756T (xx)
ME (3) ME03408B (xx)
PL (4) PL2786753T3 (xx)
PT (3) PT2786753T (xx)
RS (4) RS54648B1 (xx)
RU (4) RU2605335C2 (xx)
SI (4) SI2786753T1 (xx)
SM (1) SMT201600112B (xx)
TR (2) TR201904459T4 (xx)
WO (1) WO2012062920A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN115151259A (zh) * 2019-11-21 2022-10-04 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
CN100548988C (zh) 1998-05-11 2009-10-14 法马马有限公司 海鞘素743的代谢物
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
SE0102232L (sv) * 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
EP1572726B1 (en) 2002-10-18 2010-12-08 Pharma Mar, S.A.U. 4-methylhexanoic kahalalide f compound
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
JP2008501007A (ja) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するための方法
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
AU2005316652B2 (en) 2004-12-15 2009-07-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
ES2575518T3 (es) * 2006-02-28 2016-06-29 Pharma Mar S.A. Tratamiento mejorado de mieloma múltiple
AU2009246130A1 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with PM00 104 and another antitumor agent
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit

Also Published As

Publication number Publication date
JP2016138133A (ja) 2016-08-04
RU2767664C2 (ru) 2022-03-18
KR20210046853A (ko) 2021-04-28
DK2786753T3 (en) 2019-04-15
KR20170124641A (ko) 2017-11-10
US20180008602A1 (en) 2018-01-11
PL2637663T3 (pl) 2016-08-31
RS54648B1 (en) 2016-08-31
HK1202422A1 (en) 2015-10-02
HUE042801T2 (hu) 2019-07-29
US11590129B2 (en) 2023-02-28
CA2995018A1 (en) 2012-05-18
RU2018102078A (ru) 2019-07-19
TR201904459T4 (tr) 2019-05-21
ES2719052T3 (es) 2019-07-08
US20180078550A1 (en) 2018-03-22
ES2569180T3 (es) 2016-05-09
CY1117466T1 (el) 2017-04-26
RU2016144668A (ru) 2018-12-18
RU2018102080A3 (xx) 2021-04-12
CA2817420C (en) 2019-09-24
AU2016200191B2 (en) 2018-01-18
SI2786756T1 (sl) 2020-07-31
RU2743643C2 (ru) 2021-02-20
RU2013126630A (ru) 2014-12-20
CN103282037B (zh) 2017-04-05
EP2786754A2 (en) 2014-10-08
RS58609B1 (sr) 2019-05-31
ES2790414T3 (es) 2020-10-27
EP2786756A2 (en) 2014-10-08
AU2017276155B2 (en) 2019-03-07
HK1188572A1 (zh) 2014-05-09
CA2995033C (en) 2020-04-28
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
RS60236B1 (sr) 2020-06-30
US20180078551A1 (en) 2018-03-22
JP2013542241A (ja) 2013-11-21
CA2995025A1 (en) 2012-05-18
KR20170096065A (ko) 2017-08-23
JP6382516B2 (ja) 2018-08-29
CN105664165A (zh) 2016-06-15
AU2011328004B2 (en) 2016-07-14
JP6723815B2 (ja) 2020-07-15
WO2012062920A1 (en) 2012-05-18
CN106860870B (zh) 2020-03-31
RU2605335C2 (ru) 2016-12-20
AU2016200191A1 (en) 2016-02-04
CY1122904T1 (el) 2021-10-29
DK2786756T3 (en) 2020-04-27
RU2018102078A3 (xx) 2021-04-20
SI2786754T1 (sl) 2019-05-31
KR20170057472A (ko) 2017-05-24
ME03408B (me) 2020-01-20
EP2637663B1 (en) 2016-02-24
EP3666275A3 (en) 2020-09-09
PL2786754T3 (pl) 2019-07-31
HK1202421A1 (en) 2015-10-02
KR20170096224A (ko) 2017-08-23
EP2786753B1 (en) 2019-01-09
PL2786753T3 (pl) 2019-09-30
JP6724055B2 (ja) 2020-07-15
RU2016144668A3 (xx) 2020-03-25
SI2637663T1 (sl) 2016-05-31
PT2786753T (pt) 2019-04-24
DK2786754T3 (en) 2019-04-15
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
BR122017028568B1 (pt) 2022-03-03
JP2018100302A (ja) 2018-06-28
PT2786754T (pt) 2019-04-24
BR122017028566B1 (pt) 2022-03-03
HUE042802T2 (hu) 2019-07-29
ME02395B (me) 2016-09-20
US20230404999A1 (en) 2023-12-21
JP2018100303A (ja) 2018-06-28
KR102301175B1 (ko) 2021-09-10
EP2786755A2 (en) 2014-10-08
EP2786754A3 (en) 2014-10-29
US20130266666A1 (en) 2013-10-10
HRP20190554T1 (hr) 2019-05-03
PL2786756T3 (pl) 2020-07-13
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
BR112013011480A8 (pt) 2018-01-02
LT2786756T (lt) 2020-05-11
EP2786753A2 (en) 2014-10-08
DK2637663T3 (en) 2016-04-18
EP2786756A3 (en) 2014-10-29
CN106860870A (zh) 2017-06-20
EP2637663A1 (en) 2013-09-18
AU2011328004A1 (en) 2013-05-30
CA2995033A1 (en) 2012-05-18
ME03501B (me) 2020-04-20
RS58608B1 (sr) 2019-05-31
ES2719091T3 (es) 2019-07-08
SMT201600112B (it) 2016-07-01
RU2018102080A (ru) 2019-07-19
KR20190130078A (ko) 2019-11-20
BR112013011480A2 (pt) 2016-08-09
AU2017276157B2 (en) 2019-03-07
HK1202423A1 (en) 2015-10-02
JP6724056B2 (ja) 2020-07-15
BR112013011480B1 (pt) 2022-03-22
CN103282037A (zh) 2013-09-04
AU2017276157A1 (en) 2018-01-04
BR122017028570B1 (pt) 2022-03-03
CA2995018C (en) 2021-04-20
KR20160088956A (ko) 2016-07-26
HRP20190565T1 (hr) 2019-05-17
AU2017276155A1 (en) 2018-01-04
RU2757373C2 (ru) 2021-10-14
AU2011328004C1 (en) 2017-01-19
HUE027516T2 (en) 2016-10-28
LT2786754T (lt) 2019-04-10
KR102452022B1 (ko) 2022-10-06
CA2817420A1 (en) 2012-05-18
KR20130140071A (ko) 2013-12-23
SI2786753T1 (sl) 2019-05-31
KR101716804B1 (ko) 2017-03-15
EP2786755A3 (en) 2014-10-29
KR102247982B1 (ko) 2021-05-04
EP2786756B1 (en) 2020-03-11
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
CA2995025C (en) 2020-04-28
PT2786756T (pt) 2020-05-07
HRP20200696T1 (hr) 2020-07-24
TR201903859T4 (tr) 2019-04-22
HUE049389T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
HRP20190554T1 (hr) Kombinacijska terapija s protutumorskim antibiotikom
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
ZA201401952B (en) Immunocytokine combination therapy
ZA201300967B (en) Combination anti-cancer therapy
GB201005394D0 (en) Therapy
EP2629766A4 (en) COMBINATION THERAPY